CD19 and non-Hodgkin lymphoma: Using a mouse model of human non-Hodgkin’s lymphoma, Stadel et al. demonstrated a significant reduction in tumor burden when selinexor was administered prior to, rather than concurrently with, CD19-directed CAR-T [21].